Patient groups (n, %) | Warfarin dose (mg/day) | p Value |
---|---|---|
All (234, 100) | ||
HIV+ (112, 48) | 6.06 | |
HIV− (122, 52) | 5.72* | } p = 0.29 |
HIV+ and ARVT− (62, 55) | 5.94* | } p = 0.61 |
HIV+ and ARVT+ (50, 45) | 6.20 | } p = 0.59 |
Male (86, 100) | ||
HIV+ (44, 51) | 6.39† | |
HIV− (42, 49) | 6.49‡ | } p = 0.87 |
HIV+ and ARVT− (22, 50) | 6.92§ | } p = 0.63 |
HIV+ and ARVT+ (22, 50) | 5.87¶ | } p = 0.23 |
Female (148) | ||
HIV+ (68, 46) | 5.84† | |
HIV− (80, 54) | 5.31‡ | } p = 0.14 |
HIV+ and ARVT− (40, 58) | 5.40§ | } p = 0.84 |
HIV+ and ARVT+ (28, 42) | 6.47¶ | } p = 0.06 |
*Comparison of ARVT-naïve groups, p=0.22.
†Male versus female, p=0.29.
‡Male versus female, p=0.01.
§Male versus female, p=0.09.
¶Male versus female, p=0.3.
ARVT, antiretroviral drug therapy.